Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...

The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

The Food and Drug Administration says it has decided to continue approving COVID-19 vaccine updates for seniors and others at ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...

President Donald Trump's tax cut and spending bill faces a critical stress test on Wednesday as Republicans in the U.S. House ...

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad ...